IP Library Granted Patent US 9,556,177
Granted Patent B2
US 9,556,177 · App. 14/444,007 · Granted Jan 31, 2017

Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors

Inventors: Weirong Chen (Waltham, MA); Benjamin Lane (Chelsea, MA); Hairuo Peng (Needham, MA)
Assignees: Millennium Pharmaceuticals, Inc.; Sunesis Pharmaceuticals, Inc.
C07D487/04C07D401/12C07D401/14C07D403/12C07D413/14C07D417/12C07D417/14C07D471/04C07D473/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,556,177
App. No.
14/444,007
Granted
Jan 31, 2017
Kind
B2
Abstract

The present disclosure provides compounds having Formula II-vi-a: wherein Cy 1 , Cy 2 , and A − are defined as set forth in the specification. These compounds are synthetic intermediates used to prepare inhibitors of Raf protein kinase.

Claims (32)

1. A compound of formula II-vi-a:

wherein:

A − is a chiral anion of a chiral acid selected from the group consisting of camphorsulfonic acid (−), tartaric acid (+), malic acid (−), N-acetyl-L-leucine (−), ditoluoyl-L-tartaric acid (−), deoxycholic acid (+), quinic acid (−), camphoric acid (+), tert-butoxycarbonyl-alanine (−), tartaric acid (−), ditoluoyl-D-tartaric acid (+), camphorsulfonic acid (+), dibenzoyl-D-tartaric acid (+), L-citramalic (+), 5-acetyl mandelic acid (+), tert-butoxycarbonyl-isoleucine (+), (S)-mandelic acid, and (R)-mandelic acid;

Cy 1 is

and

Cy 2 is an unsubstituted or substituted 5-10 membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms, independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the substituents are selected from the group consisting of Cl, F, CF 3 and C 1-4 alkyl.

2. The compound of claim 1 , wherein the chiral acid is (S)-mandelic acid or (R)-mandelic acid mandelic acid.

3. The compound of claim 2 , wherein the chiral acid is (S)-mandelic acid.

4. The compound of claim 1 , wherein the chiral acid is ditoluoyl-D-tartaric acid (+).

5. The compound of claim 1 , wherein the chiral acid is ditoluoyl-L-tartaric acid (−).

6. The compound of claim 1 , wherein Cy 2 is an unsubstituted or substituted 6 membered aromatic ring having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the substituents are selected from the group consisting of Cl, F, CF 3 , and C 1-4 alkyl.

7. The compound of claim 1 , wherein Cy 2 is an unsubstituted or substituted pyridinyl, wherein the substituents are selected from the group consisting of Cl, F, CF 3 , and C 1-4 alkyl.

8. The compound of claim 1 , wherein the compound is

9. The compound of claim 3 , wherein the compound is

10. A compound of formula II-vi-b:

wherein:

A − is a chiral anion of a chiral acid selected from the group consisting of camphorsulfonic acid (−), tartaric acid (+), malic acid (−), N-acetyl-L-leucine (−), ditoluoyl-L-tartaric acid (−), deoxycholic acid (+), quinic acid (−), camphoric acid (+), tert-butoxycarbonyl-alanine (−), tartaric acid (−), ditoluoyl-D-tartaric acid (+), camphorsulfonic acid (+), dibenzoyl-D-tartaric acid (+), L-citramalic (+), 5-acetyl mandelic acid (+); and tert-butoxycarbonyl-isoleucine (+), (S)-mandelic acid, and (R)-mandelic acid;

Cy 1 is

and

Cy 2 is an unsubstituted or substituted 5-10 membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms, independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the substituents are selected from the group consisting of Cl, F, CF 3 and C 1-4 alkyl.

11. The compound of claim 10 , wherein the chiral acid is (S)-mandelic acid or (R)-mandelic acid mandelic acid.

12. The compound of claim 11 , wherein the chiral acid is (S)-mandelic acid.

13. The compound of claim 10 , wherein the chiral acid is ditoluoyl-D-tartaric acid (+).

14. The compound of claim 10 , wherein the chiral acid is ditoluoyl-L-tartaric acid (−).

15. The compound of claim 10 , wherein the compound is:

16. The compound of claim 12 , wherein the compound is

17. A compound of formula II-iv:

wherein

Cy 1 is

and

Cy 2 is an unsubstituted or substituted 5-10 membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms, independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the substituents are selected from the group consisting of Cl, F, CF 3 and C 1-4 alkyl.

18. The compound of claim 17 , wherein Cy 2 is an unsubstituted or substituted 6 membered aromatic ring having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the substituents are selected from the group consisting of Cl, F, CF 3 , and C 1-4 alkyl.

Assignments (8)
SECURITY INTEREST Recorded Jul 14, 2026
From: CYDEX PHARMACEUTICALS, INC.; LIGAND PHARMACEUTICALS INCORPORATED; METABASIS THERAPEUTICS, INC.; XOMA (US) LLC; APEIRON BIOLOGICS GMBH
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075969/0966 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2024
From: VIRACTA THERAPEUTICS, INC.
To: XOMA (US) LLC
Reel/Frame 069474/0049 →
CHANGE OF NAME Recorded Apr 14, 2023
From: SUNESIS PHARMACEUTICALS, INC.
To: VIRACTA THERAPEUTICS, INC.
Reel/Frame 063349/0100 →
MERGER Recorded May 17, 2022
From: DOT THERAPEUTICS-2, INC.; DOT THERAPEUTICS-1, INC.
To: DAY ONE BIOPHARMACEUTICALS, INC.
Reel/Frame 059936/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: MILLENNIUM PHARMACEUTICALS, INC.
To: DOT THERAPEUTICS-1, INC.
Reel/Frame 054921/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2015
From: COSSROW, JENNIFER; RAIMUNDO, BRIAN C.; TANAKA, HIROKO
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 036175/0586 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2015
From: CHEN, WEIRONG; FRANKLIN, LLOYD; GUAN, BING; JONES, JOHN HOWARD; KUMARAVEL, GNANASAMBANDAM; LANE, BENJAMIN; LITTKE, ADAM; LUGOVSKOY, ALEXEY; PENG, HAIRUO; POWELL, NOEL; VESSELS, JEFFREY; WYNN, THOMAS; XIN, ZHILI
To: BIOGEN IDEC MA INC.
Reel/Frame 036175/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2015
From: BIOGEN IDEC MA INC.
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 036175/0639 →
Continuity (4)
Division 13657506 · Oct 22, 2012
Continuation 12164762 · Jun 30, 2008
Provisional Application 60947291 · Jun 29, 2007
Related Publication 20150080568A1 · Mar 19, 2015